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CASE REPORT
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Abstract: This is a case of a 70-year-old man with severe peripheral neuropathy, type 2 diabetes and 
progressively worsening cerebellar ataxia. He was found to have circulating antigliadin and antire-
ticulin antibodies compatible with celiac disease in the absence of intestinal pathology. The peripheral 
neuropathy improved with a gluten-free diet, antioxidants and intravenous immunoglobulin, whereas 
the ataxia did not. This case illustrates the need to test for celiac disease in patients with idiopathic 
ataxia and peripheral neuropathy and the need for alternative therapies for ataxia.
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Introduction
The combination of ataxia and peripheral neuropathy (PN) may be associated with a 
variety of conditions such as paraneoplastic syndromes, celiac disease (CD), Sjogren’s 
syndrome, chronic inﬂ  ammatory demyelinating polyneuropathy, and Miller-Fisher 
syndrome, (Honnorat et al 2001; Lang et al 2003; Koller et al 2005). CD is a multige-
netic T-cell mediated autoimmune disease where intolerance develops to the dietary 
protein ‘gluten’. CD typically presents with gastrointestinal manifestations but in some 
cases ataxia can be the presenting sign. Other extraintestinal manifestations include 
iron-deﬁ  ciency anemia, osteoporosis, cryptogenic hypertransaminasemia, recurrent 
abortion, autoimmune diseases which are now recognized to be more common in the 
absence of gastrointestinal symptoms in patients with gluten-sensitive enteropathy. 
It has been estimated from prevalence studies that for every patient with CD who 
presents with gartrointestinal symptoms, there are eight patients with silent disease. 
Since diabetes is a major cause of PN (Dyck et al 1993; Vinik et al 2006) there is com-
placency about seeking alternative causes of neurological syndromes in such patients. 
Autoimmune pathogenetic mechanisms have been implicated in neuropathy in diabetes 
(Granberg et al 2005). It is unclear whether the antibodies are pathogenic or innocent 
bystanders (Vinik et al 2005a), but there is little doubt that there is a greater frequency 
of inﬂ  ammatory demyelinating neuropathies in people with diabetes than in the general 
population (Sharma et al 2002). The association of cerebellar ataxia and PN in diabetes 
has been reported in a patient with circulating GAD antibodies (Iwasaki et al 2001). 
The prevalence of CD in children with juvenile diabetes is at least 4.6% (Aktay et al 
2001) and is known it is known to be a hall mark of type-1 diabetes. However, CD 
may occur in type 2 diabetes or in latent autoimmune diabetes of adult (Sanchez et al 
2007). Thus, it is not surprising to ﬁ  nd CD in older males with diabetes. We present a 
case of cerebellar ataxia associated with CD without gastrointestinal involvement in a Journal of Multidisciplinary Healthcare 2008:1 94
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patient with well-controlled diabetes in whom treatment of 
the autoimmunity reversed the PN, but not the ataxia.
Case report
A 70-year-old Caucasian male with a 3 ½ year history of type 
2 diabetes, presented with complaints of unsteadiness. He 
had numbness in his feet and erectile dysfunction. He took 
irbersartan for hypertension and had a strong family history 
of type 2 diabetes but no autoimmune diseases.
His musculoskeletal system showed bilateral mild 
wasting of the quadriceps and total loss of vibration sensation 
in the feet. Pinprick sensation was reduced in both his lower 
limbs to the level of the ankles but only a mild reduction in 
the upper limbs. Tendon reﬂ  exes were intact. Romberg’s sign 
was negative. Tandem stand test was strongly positive as was 
the one-legged stand test. Two months later he exhibited gait 
ataxia, hypermetria, and intention tremor.
Extensive testing for possible causes was done. 
Paraneoplastic antibodies, urinary heavy metal excretion, 
serum electrophoresis, ANA, RPR, and HIV tests were 
negative. A MRI of the spine and brain did not reveal any 
pathology, PET scan of the lungs for occult malignancy 
was negative and CSF was normal. Vitamin E and vitamin 
B12, TSH, ceruloplasmin, and lactic acid levels were all 
normal. His HbA1c was 6.4% .Since this clinical pre-
sentation was distinctly unusual for diabetes, we investi-
gated further for auto-immune neuropathy and incubated 
his serum with N1E-115 neuroblastoma cells which 
showed apoptotic cell death conﬁ  rming the autoimmune 
etiology (Pittenger et al 1997).
Electromyography showed supranormal conduction 
velocities over the peroneal, tibial, medial, ulnar, and sural 
nerves but low amplitudes indicating a mild axonal form of 
neuropathy. Quantitative sensory testing (QST) revealed a 
mild large-ﬁ  ber neuropathy with impaired vibration percep-
tion and relatively intact warm and cold thermal perception 
in the feet. All these findings were compatible with a 
metabolic disease such as diabetes. Hence, diet, exercise 
and oral hypoglycemic therapy were initiated to control the 
diabetes and in light of the strongly positive effects of his 
serum on immunotoxicity assay, we initiated intravenous 
immunoglobulin (IVIg) therapy along with oral antioxidant 
therapy (Vitamin C, 500 mg/day; Vitamin E, 400 IU/day; 
alphalipoic acid,1200 mg/day; and dihomogammalinolenic 
acid, 3900 mg/day). The magnetic resonance scan of his brain 
revealed evidence of moderate cerebellar atrophy.
Six months later, his neuropathy had improved except 
for mild impairment of vibration perception. However, 
cerebellar signs were still present. By this time he had 
completed two infusions of intravenous immunoglobulin 
(IVIg) (1 g/kg/day × 2) but unfortunately he developed a 
centripetal rash after the 2nd infusion, and no further IVIg 
was given. The patient’s serum remained toxic to neuronal 
cells in culture despite the administration of IVIg. Table 1 
shows the improvement in QST and autonomic nerve func-
tion tests at presentation and 17 months into treatment.
These progressively worsening cerebellar signs were 
thought to be due to an autoimmune process, as the serum 
was very toxic to neuroblastoma cells. Antigliadin IgG, 
antigliadin IgA and antireticulin antibodies were found to 
be positive among many other antibody panels that were 
investigated. Other antibodies including, paraneoplastic 
antibodies, anti-GAD antibodies, antithymoglobin, antimi-
crosomal, anti-R1, anti-Ma/Ta, antiendomysial antibodies, 
anti-Yo-antibody, anti-Hu antibody, antineural antibodies 
(ANNA-1 and ANNA-2) and Lyme titers were negative 
(these tests were performed by LabCorp, Burlington, NC). 
Small bowel studies including esophagogastroduodenoscopy 
and biopsies of small bowel failed to show any evidence of 
CD. Though there was no biopsy evidence of CD, he was 
advised to embark on a gluten-free diet based on case reports 
that suggested that ataxia could be the sole manifestation of 
CD in the absence of gastrointestinal pathology and based 
on antibody positivity. There was also the possibility that the 
intestinal biopsy had missed the affected site.
After 2-months on a gluten-free diet, his peripheral 
neuropathy showed further improvement but he still had 
all the signs of cerebellar dysfunction supporting the notion 
of different mechanisms for the cerebellar ataxia and the 
peripheral neuropathy. After 20 months on the diet, all the 
celiac antibody titers became normal and the PN showed 
progressive improvement but the cerebellar function did not. 
Figure 1 shows the clinical improvement over time.
Discussion
This patient has progressive cerebellar ataxia, improving 
peripheral neuropathy and decreasing titers of celiac anti-
bodies. Hence, it is compelling to consider CD as the cause 
of his condition. Cerebellar ataxia could be the only mani-
festation of an otherwise occult CD in this patient. Sensory 
axonal neuropathies and small ﬁ  ber polyneuropathies are 
the most frequently reported types of peripheral neuropathy 
in CD (Chin et al 2003). There are reports to suggest that 
ataxia could be the sole manifestation of CD especially in 
people with a genetic susceptibility (Hadjivassiliou et al 
1998; Bushara et al 2001). There is growing evidence of Journal of Multidisciplinary Healthcare 2008:1 95
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Table 1 Quantitative measures of peripheral sensory threshold indices and autonomic function done at the time of presentation and 
after 17 months of treatment. Measures of peripheral neuropathy are vibration and pressure sensations, warm and cold perceptions 
and painful perception (Vinik et al 1995). The E/I (exipiratory/ inspiratory ratio), 30:15 stand test and valsalva are measures of auto-
nomic nerve function (Vinik and Erbas 2001)
Neuropathy 
t tests(units)
At presentation After 17 months Normal values 
for 90% speciﬁ  city
Vibration (volts) 9.11 3.63 0–6.1
Pressure (log g) 4.13 3.58 0–3.95
Cold perception (°C) 8.6 9.2 0–10.5
Warm Perception (°C) 10.3 9.3 0–12.4
Cold pain(°C) 24 11.1 0–23.3
Warm pain (°C) 15.5 10.4 0–17.7
E/I 1.11 1.06 1.08
Valsalva 1.57 1.21 1.15
30:15 ratio 1.13 1.05 1.08
the association of CD with many neurological disorders 
(Hadjivassiliou et al 1996). These conditions include 
cerebellar ataxia, PN, epilepsy, dementia, and depression. 
Among these, cerebellar ataxia, PN and memory impairment 
are the most commonly seen associations (Hadjivassiliou 
et al 1998; Luostarinen et al 1999; Pereira et al 2004). There 
is also some suggestion that migraine, encephalopathy, 
chorea, brain-stem dysfunction, myelopathy, mononeuritis 
multiplex and Guillian-Barre like syndrome could be the 
presenting extra-intestinal manifestations of CD with or 
without intestinal pathology (Bushara 2005).
Although ataxia is believed to be due to immunological 
damage to the cerebellum, posterior column, and peripheral 
nerves (Hadjivassiliou et al 1998), it is unclear whether there 
is a common pathogenic mechanism that affects both the 
nervous system and the gastrointestinal tract. Ataxia in CD 
can be due to malabsorption and associated vitamin deﬁ  ciency 
(Hagen et al 2000). There is a report where parenteral vitamin 
E administration improved the clinical and neurophysiological 
signs of CD in a vitamin E-depleted patient with this disease 
(Battisti et al 1996). However, our patient had normal Vitamin 
E levels and had received vitamin E.
Figure 1 This ﬁ  gure represents the progressive changes in central and peripheral nervous system scores. The central nervous system (CNS) signs score is the sum of the 
number of positive cerebellar signs. The total peripheral neuropathy impairment scores and sensory scores were obtained from our clinical evaluation scoring system (Vinik 
et al 2005b) modiﬁ  ed from the Rochester Diabetic Neuropathy Study (Dyck et al 1992) . In this system a score of 1 or 0 is given for the presence or absence of neuropathy 
symptom respectively. Motor, sensory and autonomic nervous systems are evaluated and given scores on a scale of 0 to 4, 0 being no impairment and 4 being severe impairment. 
Antioxidant treatment instituted at point A, IV Ig infusion instituted at point B and Point C is when gluten free diet was started.
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A gluten-free diet is the main modality of treatment for 
CD. Other therapies include IVIg and inﬂ  iximab (Chin and 
Latov 2005). Although there are reports that gluten-free 
diet has improved survival and quality of life, facilitated 
the normal growth and development in infants, prevented 
osteopenia and decreased the risk of T-cell lymphoma in 
adults, its effect on the nervous system has been variable 
(Lefﬂ  er et al 2003). There are reports where ataxia and PN 
persisted or even progressed with gluten free diet (Lefﬂ  er 
et al 2003; Chin and Latov 2005).
Our patient demonstrates a dichotomy between the 
responses of PN, autonomic neuropathy and cerebellar 
ataxia to a gluten-free diet. Nonetheless the frequency of 
coexistence of CD in diabetes and the responsiveness of PN 
to therapy would encourage a search for the presence of CD 
in patients with diabetes and neuropathy. Strikingly, the PN 
improved with measures to reduce autoimmunity supporting 
the notion that there may be an autoimmune mechanism for 
damage to peripheral nerves that can be resolved. Unfortu-
nately, this does not appear to be the case for the cerebellar 
component for reasons that are not apparent at this point 
in time. The occurrence of cerebellar ataxia emphasizes 
the need to consider CD and requires further investigation 
into possible pathogenetic mechanisms which appear to be 
distinct from that of the PN.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
Aktay AN, Lee PC, Kumar V, et al. 2001. The prevalence and clinical char-
acteristics of celiac disease in juvenile diabetes in Wisconsin. J Pediatr 
Gastroenterol Nutr, 33:462–5.
Battisti C, Dotti MT, Formichi P, et al. 1996. Disappearance of skin lipo-
fuscin storage and marked clinical improvement in adult onset coeliac 
disease and severe vitamin E deﬁ  ciency after chronic vitamin E mega-
therapy. J Submicrosc Cytol Pathol, 28:339–44.
Bushara KO. 2005. Neurologic presentation of celiac disease. Gastroen-
terology, 128:S92–S97.
Bushara KO, Goebel SU, Shill H, et al. 2001. Gluten sensitivity in sporadic 
and hereditary cerebellar ataxia. Ann Neurol, 49:540–3.
Chin RL, Latov N. 2005. Peripheral neuropathy and celiac disease. Curr 
Treat Options Neurol, 7:43–8.
Chin RL, Sander HW, Brannagan TH, et al. 2003. Celiac neuropathy. 
Neurology, 60:1581–5.
Dyck PJ, Karnes JL, O’Brien PC, et al. 1992. The Rochester Diabetic 
Neuropathy Study: reassessment of tests and criteria for diagnosis and 
staged severity. Neurology, 42:1164–70.
Dyck PJ, Kratz KM, Karnes JL, et al. 1993. The prevalence by staged sever-
ity of various types of diabetic neuropathy, retinopathy, and nephropathy 
in a population-based cohort: the Rochester Diabetic Neuropathy Study. 
Neurology, 43:817–24.
Granberg V, Ejskjaer N, Peakman M, et al. 2005. Autoantibodies to 
autonomic nerves associated with cardiac and peripheral autonomic 
neuropathy. Diabetes Care, 28:1959–64.
Hadjivassiliou M, Gibson A, Davies-Jones GA, et al. 1996. Does 
cryptic gluten sensitivity play a part in neurological illness? Lancet, 
347:369–71.
Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, et al. 1998. Clinical, 
radiological, neurophysiological, and neuropathological characteristics 
of gluten ataxia. Lancet, 352:1582–5.
Hagen EM, Gjerde IO, Vedeler C, et al. 2000. [Neurological diseases associ-
ated with celiac disease]. Tidsskr Nor Laegeforen, 120:439–42.
Honnorat J, Saiz A, Giometto B, et al. 2001. Cerebellar ataxia with anti-
glutamic acid decarboxylase antibodies: study of 14 patients. Arch 
Neurol, 58:225–30.
Iwasaki H, Sato R, Shichiri M, et al. 2001. A patient with type 1 diabetes 
mellitus and cerebellar ataxia associated with high titer of circulating 
anti-glutamic acid decarboxylase antibodies. Endocr J, 48:261–8.
Koller H, Kieseier BC, Jander S, et al. 2005. Chronic inﬂ  ammatory demy-
elinating polyneuropathy. N Engl J Med, 352:1343–56.
Lang B, Dale RC, Vincent A. 2003. New autoantibody mediated disorders 
of the central nervous system. Curr Opin Neurol, 16:351–7.
Lefﬂ  er D, Saha S, Farrell RJ. 2003. Celiac disease. Am J Manag Care, 
9:825–31.
Luostarinen L, Pirttila T, Collin P. 1999. Coeliac disease presenting with 
neurological disorders. Eur Neurol, 42:132–5.
Pereira AC, Edwards MJ, Buttery PC, et al. 2004. Choreic syndrome and 
coeliac disease: a hitherto unrecognized association. Mov Disord, 
19:478–82.
Pittenger GL, Liu D, Vinik AI. 1997. The apoptotic death of neuroblastoma 
cells caused by serum from patients with insulin-dependent diabetes and 
neuropathy may be Fas-mediated. J Neuroimmunol, 76:153–60.
Sanchez JC, Cabrera-Rode E, Sorell L, et al. 2007. Celiac disease associated 
antibodies in persons with latent autoimmune diabetes of adult and type 
2 diabetes. Autoimmunity, 40:103–7.
Sharma KR, Cross J, Farronay O, et al. 2002. Demyelinating neuropathy 
in diabetes mellitus. Arch Neurol, 59:758–65.
Vinik A, Ullal J, Parson HK, et al. 2006. Diabetic neuropathies: clinical 
manifestations and current treatment options. Nat Clin Pract Endocrinol 
Metab, 2:269–81.
Vinik AI, Anandacoomaraswamy D, Ullal J. 2005a. Antibodies to neu-
ronal structures: innocent bystanders or neurotoxins? Diabetes Care, 
28:2067–72.
Vinik AI, Erbas T. 2001. Recognizing and treating diabetic autonomic 
neuropathy. Cleve Clin J Med, 68:928–44.
Vinik AI, Suwanwalaikorn S, Stansberry KB, et al. 1995. Quantitative 
measurement of cutaneous perception in diabetic neuropathy. Muscle 
Nerve, 18:574–84.
Vinik EJ, Hayes RP, Oglesby A, et al. 2005b. The development and valida-
tion of the Norfolk QOL-DN, a new measure of patients’ perception 
of the effects of diabetes and diabetic neuropathy. Diabetes Technol 
Ther, 7:497–508.